ARYx Therapeutics Inc
OTC:ARYX

Watchlist Manager
ARYx Therapeutics Inc Logo
ARYx Therapeutics Inc
OTC:ARYX
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 33.5 USD

ARYx Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ARYx Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
ARYx Therapeutics Inc
OTC:ARYX
EPS (Diluted)
-$1
CAGR 3-Years
8%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

ARYx Therapeutics Inc
Glance View

Market Cap
33.5 USD
Industry
Pharmaceuticals

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

ARYX Intrinsic Value
Not Available

See Also

What is ARYx Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.2 USD

Based on the financial report for Dec 31, 2009, ARYx Therapeutics Inc's EPS (Diluted) amounts to -1.2 USD.

What is ARYx Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
0%

Over the last year, the EPS (Diluted) growth was 27%. The average annual EPS (Diluted) growth rates for ARYx Therapeutics Inc have been 8% over the past three years .

Back to Top